BioWorld Asia

Nov. 14, 2007

Antisense Pharma Gets $39.5M For Antisense Glioma Product

Antisense Pharma GmbH raised €27 million (US$39.5 million) in a third investment round funded solely by MIG AG, which also was the only investor in its €18 million funding round two years ago. (BioWorld International) Read More

Acambis Partners West Nile Vaccine In $80M Sanofi Deal

Novel Obesity Gene Plays A Role In Modifying DNA

Actelion Advances Clazosentan Into Phase III Vasospasm Study

Peptech Reinvents Itself As Arana, Shifts To Antibodies

Cerep Sells Hesperion To CRO Averion In €25M Deal

No Abstract Read More

Activists Strike At European Industry's Lobbying Power

Other News To Note

LSD Deal Brings Amicus $50M Now, $390M Later

As Big Pharma Model Falters, Biotech Rides To The Rescue

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...

Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

AI drug developer Insilico to raise $292 million in Hong Kong IPO

BioWorld

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...